Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: In vitro and in vivo preclinical studies

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1782-1790

  Peyrode, Caroline ^a   Weber, Valérie ^a   David, Emmanuelle ^b   Vidal, Aurélien ^a   Auzeloux, Philippe ^a   Communal, Yves ^c   Dauplat, Marie Mélanie ^c   Besse, Sophie ^a   Gouin, François ^b   Heymann, Dominique ^b   Chezal, Jean Michel ^a   Rédini, François ^b   Miot Noirault, Elisabeth ^a  

^a INSERM   (France)

^b Universite de Nantes   (France)

^c CLCC Jean Perrin   (France)

Author keywords

99mTc NTP 15 5 radiotracer; Antitumour activity; Melphalan; Orthotopic model; Proteoglycans; Quaternary ammonium; Swarm Rat chondrosarcoma

Indexed keywords

ALCIAN BLUE; MELPHALAN; PROTEOGLYCAN; QUATERNARY AMMONIUM DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM N [TRIETHYLAMMONIUM] 3 PROPYL 15ANE N5 TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; NONHUMAN; OSTEOSARCOMA CELL; PRIMARY TUMOR; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ANALYSIS; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROSARCOMA; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MELPHALAN; PROTEOGLYCANS; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84866740975     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9663-z     Document Type: Review

References (27)

1. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovee JV (2008) The clinical approach towards chondrosarcoma. Oncologist 13:320-329
2. Riedel RFLN, Dodd L, Kirsch D, Martinez S, Brigman BE (2009) The clinical management of chondrosarcoma. Curr Treat Options Oncol 10:94-106
3. Bovee JV, Hogendoorn PC, Wunder JS, Alman BA (2010) Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 10:481-488
4. Juillerat-Jeanneret L, Schmitt F (2007) Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev 27:574-590
5. Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, Chavignon O, Maublant J, Teulade JC, Madelmont JC, Moins N (2008) Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4- iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 51:3133-3144
6. Rapp M, Giraud I, Maurizis JC, Galmier MJ, Madelmont JC (2003) Synthesis and in vivo biodisposition of [14C]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug. Bioconjug Chem 14:500-506
7. Aigner T (2002) Towards a new understanding and classification of chondrogenic neoplasias of the skeleton: biochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch 441:219-230
8. Olsen GD, Chan EM, Riker WK (1975) Binding of d-tubocurarine di (methyl-14C) ether iodide and other amines to cartilage, chondroitin sulfate and human plasma proteins. J Pharmacol Exp Ther 195:242-250
9. Maurizis JC, Ollier M, Nicolas C, Madelmont JC, Garrigue H, Veyre A (1992) In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts. Biochem Pharmacol 44:1927-1933
10. Larsson B, Nilsson M, Tjälve H (1981) The binding of inorganic and organic cations and H1 to cartilage in vitro. Biochem Pharmacol 30:2963-2970
11. Giraud I, RappM, Maurizis JC, Madelmont JC (2000) Application to a cartilage targeting strategy: synthesis and in vivo biodistribution of (14)C-labeled quaternary ammonium-glucosamine conjugates. Bioconjug Chem 11:212-218
12. Vidal A, Chezal JM, Mounetou E (2010) New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation. Eur J Med Chem 45:405-410
13. Nicolas C, Borel M, Maurizis JC, Gallais N, Rapp M, Ollier M, Verny M, Madelmont JC (2000) Synthesis of N-quaternary ammonium [3H] and [99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging. J Labelled Comp Radiopharm 43:585-594
14. Giraud I, Rapp M, Maurizis JC, Madelmont JC (2002) Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma. J Med Chem 45:2116-2119
15. O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421-5426
16. Guide for the care and use of laboratory animals (1996) National Academy Press, Washington
17. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577
18. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F (2002) Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 17:1103-1111
19. Polin L, White K, Kushner J, Paluch J, Simpson C, Pugh S, Edelstein MK, Hazeldine S, Fontana J, LoRusso P, Horwitz JP, Corbett TH (2002) Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20:13-22
20. Miot-Noirault E, Gouin F, Vidal A, Rapp M, Maublant J, Askienazy S, Chezal JM, Heymann D, Redini F, Moins N (2009) First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med 50:1541-1547
21. Bielawski K, Bielawska A (2008) Small-molecule based delivery systems for alkylating antineoplastic compounds. ChemMedChem 3:536-542
22. De Jong M, Maina T (2010) Of mice and humans: are they the same? Implications in cancer translational research. J Nucl Med 51:501-504
23. Hascall GK (1980) Ultrastructure of the chondrocytes and extracellular matrix of the swarm rat chondrosarcoma. Anat Rec 198:135-146
24. Breitkreutz D, Diaz de Leon L, Paglia L, Gay S, Swarm RL, Stern R (1979) Histological and biochemical studies of a transplantable rat chondrosarcoma. Cancer Res 39:5093-5100
25. Hamm CA, Stevens JW, Xie H, Vanin EF, Morcuende JA, Abdulkawy H, Seftor EA, Sredni ST, Bischof JM, Wang D, Malchenko S, Bonaldo Mde F, Casavant TL, Hendrix MJ, Soares MB (2010) Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors. BMC Cancer 10:471
26. Kenan S, Steiner GC (1991) Experimental transplantation of the Swarm rat chondrosarcoma into bone: radiological and pathological studies. J Orthop Res 9:445-451
27. Sakimura R, Tanaka K, Yamamoto S, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Li Y, Iwamoto Y (2007) The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 13:275-282